The effect of tailoring on the implementation of guideline recommendations for the recognition, diagnosis and allocation of care for anxiety and depression in primary care

The effect of tailoring on the implementation of guideline recommendations for the recognition, diagnosis and allocation of care for anxiety and depression in primary care - Effect of tailoring on the implementation of guidelines in primary care

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35351

Enrollment

396

Registered

2009-11-18

Start date

2010-10-26

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorders and Depression

Interventions

The interventions to be implemented in both groups are derived from the national guidelines for anxiety disorders and depression and comprise the phase of recognition, diagnosis and needs assessment

2. Making the diagnosis and recording this in the General Practitioner Information System

3. Discussion of the diagnosis and treatment options with the patient and providing psycho-education to diagnosed patients in accordance with the protocol

4. Making the distinction between mild/non-complex problems and severe/complex problems and determining suitable initial treatment on this basis (stepped care allocation), in consultation with the p

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients from 18 years and older whose first score on the Dutch version of the extended Kessler-10 (EK-10) is 20 or higher and/or at least once a yes on the added questions 11 till 16

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Primary outcome measurement at general practitioner level is: 1. Change in the number of patients who have been given the 4DQS as screener.	—

Secondary

Measure	Time frame
Other secondary outcomes are: At patient level: 2. Change in the symptoms of anxiety and depression measured with the Four Dimensional Symptom Questionnaire, the 4DSQ. 3. Change in functioning, measured with the WHO-DASS; 4. Experiences with the care, measured with the Quality Of care Through the patient's Eyes (QUOTE, CQIndex) 5. Quality-of-life measured with the EuroQol (EQ-5D) 6.Care utilization, illness and work measured with the Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P/prodisq). At general practitioner level 7. Increase in registered diagnoses of anxiety and depression; 8. Change in anti-depressant prescribing, number of references, number of consultations for anxiety and depression.	—

Measure

Time frame

Other secondary outcomes are: At patient level: 2. Change in the symptoms of anxiety and depression measured with the Four Dimensional Symptom Questionnaire, the 4DSQ. 3. Change in functioning, measured with the WHO-DASS; 4. Experiences with the care, measured with the Quality Of care Through the patient's Eyes (QUOTE, CQIndex) 5. Quality-of-life measured with the EuroQol (EQ-5D) 6.Care utilization, illness and work measured with the Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P/prodisq). At general practitioner level 7. Increase in registered diagnoses of anxiety and depression; 8. Change in anti-depressant prescribing, number of references, number of consultations for anxiety and depression.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)